Skip to main content

CAR-T Therapies Resource Center

Featured

Conference Coverage
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Conference Coverage
12/08/2021
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways
News
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access
03/15/2021
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan...
03/15/2021
Journal of Clinical Pathways
News
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways

Expert Insights

Ajeet Gajra, MD, FACS
Videos
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Editor Insights
04/19/2018
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to...
04/19/2018
Journal of Clinical Pathways
Guest Blog
03/15/2018
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi...
03/15/2018
Journal of Clinical Pathways
Editor Insights
02/02/2018
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill...
02/02/2018
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Interview
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology

Newsfeed

Conference Coverage
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
News
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
08/24/2020
The Centers for Medicare and Medicaid Services (CMS) proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor T-cell (CAR-T) therapies. Under the new policy,...
The Centers for Medicare and Medicaid Services (CMS) proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor T-cell (CAR-T) therapies. Under the new policy,...
The...
08/24/2020
Journal of Clinical Pathways
News
05/13/2020
The Centers for Medicare & Medicaid Services (CMS) has released its proposed Hospital Inpatient Prospective Payment System (IPPS) rule for 2021. Included in the proposed rule is a new Medicare Severity-Diagnosis...
The Centers for Medicare & Medicaid Services (CMS) has released its proposed Hospital Inpatient Prospective Payment System (IPPS) rule for 2021. Included in the proposed rule is a new Medicare Severity-Diagnosis...
The...
05/13/2020
Journal of Clinical Pathways
News
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

Interactive Features

SPONSORED QUIZ BY SANOFI
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways